CYP-001

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

AppLovin company profile: How Axon AI is taking performance advertising beyond mobile gaming

Infographic showing the Rincon lithium project in Salta, Argentina, with a lithium processing facility and key figures including a US$2.5 billion cost, 60,000-tonne annual capacity, and a 2028 first-production target.

Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline

Supreme Court says children have fundamental right to internet access, rejects blanket bans

Editorial infographic showing affordable fragrance mists becoming a growth area for beauty companies, with product imagery and panels highlighting stronger US mass-market fragrance growth, new launches from major beauty groups, and the key business question of whether lower-priced scents can drive repeat purchases.

Why L’Oréal, Coty and Unilever are betting on affordable fragrance mists

Cynata Therapeutics (ASX: CYP) completes Phase 2 enrolment for CYP-001 as investors refocus on June 2026 data inflection

Cynata Therapeutics completes Phase 2 enrolment for CYP-001, shifting focus to June 2026 data. Read what this means for strategy, risk, and valuation.

μFR system
αvβ6-integrin
α4β7 integrin
Þorgerður Katrín Gunnarsdóttir
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynyz
ZYNRELEF

December 15, 2025